PFE (Pfizer) How high will it go? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go?

PFE 25.32

+1.1%

2:30 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (6397)	12/1/1998 7:46:00 PM
From: Jim Lamb	Read Replies (1) of 9523

Anthony,all. Looks like adding a warning label on the COX2 drugs about G.I. symptoms is all important. -------------------------------------------------------------------------------- Dec 01, 1998 (6:16 PM ET) - The Motley Fool Evening News Life sciences company Monsanto Co. (NYSE:MTC - news) fell $1 13/16 to $43 1/2 after its long-awaited Celebrex pain management drug won a recommendation for approval from an Federal Drug Administration advisory panel today as a treatment for both osteoarthritis and rheumatoid arthritis. While the recommendation was good news, the panel left unresolved the important question of whether the new drug will carry the standard gastro-intestinal warning label that is affixed to other painkillers. The absence of stomach irritation side effects was to be a major selling point for Celebrex, which is the first of a new line of drugs called Cox-II inhibitors. The drugs interfere with the Cox-II enzyme that is associated with pain and swelling, hopefully without messing too much with the stomach-acid-shielding Cox-I enzyme. Monsanto and Celebrex marketing partner Pfizer (NYSE:PFE - news) are hoping that a positive ruling on the labeling question will be handed down by the FDA soon, or at least before the agency reviews the approval application for Merck's (NYSE:MRK - news) rival Cox-II inhibitor, Vioxx.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next